Research programme: Crohn's disease therapeutics - Amgen/TScan Therapeutics
Latest Information Update: 24 May 2023
At a glance
- Originator Amgen; TScan Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Crohn's disease